Goldline Pharmaceutical IPO- Company Analysis
Goldline Pharmaceutical IPO under the SME IPO category is a bookbuild issue of Rs. 11.61 Cr by Goldline Pharmaceutical Limited and is a promoter of pharmaceutical items under the "Goldline" brand. There are five categories within its product line:-
Goldline Pharma: There are 42 products in this category that are intended for specialists such as physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, and urology.
Goldline Cardinal: This category provides 54 medical-related products designed for the Specialty division.
Goldline Aayushman: This category includes eighteen goods made for the Specialty division, which serves medical professionals like general practitioners, pediatricians, child specialists, and neonatologists.
Goldline InLife: This category has 22 goods designed specifically for the Specialty division, catering to physicians, super specialty surgeons, critical care consultants, and intensivists.
Goldline Wellness: There are ten goods in this category. Supportive care is essential to cancer treatment.
Goldline Pharmaceutical IPO Details
The Goldline Pharmaceutical IPO date of opening is 12 May 2026, its initial public offering will end on 14 May, IPO allotment on May 15 and refund initiation on May 18, 2026.
The Rs. 11.61 crore new SME IPO comprises a wholly fresh issue of 0.27 Cr shares.
The Goldline Pharmaceutical IPO listing date (expected) might be on Tuesday, May 19, 2026, and listing at the BSE and SME.
The Goldline Pharmaceutical IPO price band is Rs. 41 to Rs. 43.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
May 12, 2026 |
|
IPO Closing Date |
May 14, 2026 |
|
IPO Allotment Date |
May 15, 2026 |
|
Refund Initiation |
May 18, 2026 |
|
IPO Listing Date |
May 19, 2026 |
Click to open demat account and apply for the IPO.
child porn available, child trafficking available contact now to buy child for pleasure
Company Financials
(Amount in Cr)
|
Particulars |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Assets |
26.28 |
22.93 |
19.39 |
|
Total Income |
28.06 |
23.57 |
19.85 |
|
Profit After Tax |
2.83 |
1.81 |
0.26 |
|
EBITDA |
5.83 |
4.30 |
2.19 |
|
Net Worth |
10.35 |
7.86 |
5.89 |
|
Reserves and Surplus |
1.65 |
3.76 |
2.08 |
|
Total Borrowing |
11.03 |
11.13 |
10.83 |
Cash Flows
(Amount in lac)
|
Net Cash Flow |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Net Cash Flow Operating Activities |
232.14 |
292.24 |
239.12 |
|
Net Cash Flow Investing Activities |
16.23 |
(110.88) |
(103.49) |
|
Net Cash Flow Financing Activities |
(203.38) |
(107.78) |
(144.31) |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company desires to use the Net Proceeds from the Issue to fulfill its following goals:
-
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the Company. ~ Rs. 8.35 Cr.
-
General Corporate Purposes.
Listed Peers of Goldline Pharmaceutical Ltd.
|
Name of the Company |
Face Value (Per Share) |
EPS (Rs) |
P/E Ratio |
|
Mono Pharmacare Limited |
10 |
1.75 |
7.57 |
|
Chandra Bhagat Pharma Limited |
10 |
1.14 |
28.94 |
Valuation
|
KPI |
Value (Mar 31, 2025) |
|
ROE |
35.83% |
|
ROCE |
38.45% |
|
Debt/Equity |
1.50 |
|
RoNW |
27.37% |
|
PAT Margin |
10.09% |
|
EBITDA Margin |
20.78% |
|
PB Value |
3.47 |
Evaluation of P/E Ratio
Considering the period ended on FY 2025 with an EPS of Rs. 4.10 from the last year, the resulting P/E ratio is 10.48x.
Explore the Amba Auto Sales & Services IPO.
IPO's Strengths
-
Experienced Promoters and Management Team with Industry Knowledge and a Track Record
-
Asset-light Business Model and Competitive Products
-
Scalable Business Model
-
Wide and Diverse Range of Product Offerings.
IPO's Weaknesses
-
Dependence on third-party manufacturers.
-
Regulatory compliance and filing risk.
-
Market analysis and product selection risk
Goldline Pharmaceutical IPO GMP (Grey Market Premium)
Goldline Pharmaceutical IPO GMP today is Rs. 15 as of 19 May 2026, while writing this information.
Goldline Pharmaceutical IPO Summary
|
IPO Opening & Closing Date |
12 May, 2026 to 14 May, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 41 to Rs. 43 per Share. |
|
Lot Size |
3000 Shares |
|
Issue Size |
27,00,000 Shares (Rs. 12 Cr) |
|
Offer for Sale |
- |
|
Fresh Issue |
25,62,000 Shares (Rs. 11 Cr) |
|
Listing at |
BSE, SME |
|
Issue Type |
Bookbuild issue IPO |
|
Registrar |
Bigshare Services Pvt. Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (6000 Shares) for Rs. 2,58,000, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (9000 Shares) for Rs. 3,87,000.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Goldline Pharmaceutical IPO Allotment Status
To check the Goldline Pharmaceutical IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Goldline Pharmaceutical Ltd.
-
Amol Laxmikant Mujumdar
-
Swapan Premprakash Khandelwal
|
Pre-Issue Promoter Shareholding |
79.70% |
|
Post-Issue Promoter Shareholding |
- |
IPO Lead Managers
Cumulative Capital Pvt. Ltd.
Dividend Policy
The company has not paid a dividend since its incorporation.
Conclusion
With a price range of ₹41–₹43 per share, Goldline Pharmaceutical IPO is a BSE SME book-built issuance of ₹11.61 crore that will open on May 12, 2026, and close on May 14, 2026. The company, which sells pharmaceuticals under the "Goldline" brand, intends to use IPO proceeds primarily for general corporate operations and loan repayment or prepayment.
As of May 11, 2026, their FY2025 financials indicate ₹28.06 crore total income, ₹2.83 crore PAT, 35.83% ROE, 38.45% ROCE, 10.48x P/E, and GMP of ₹16.
Other Related Blogs:- OnEMI Technology Solutions IPO, Value 360 Communications IPO
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company Click Here to Download the DRHP.
Click Here To Stay Updated With The Upcoming IPOs.
DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.
